Cognitive performance and cerebrospinal fluid biomarkers of neurodegeneration: A study of patients with bipolar disorder and healthy controls

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Rolstad, Sindre ^a   Jakobsson, Joel ^a   Sellgren, Carl ^b   Ekman, Carl Johan ^b   Blennow, Kaj ^a   Zetterberg, Henrik ^a,c,d   Pålsson, Erik ^a   Landén, Mikael ^a,b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; AMYLOID PRECURSOR PROTEIN ALPHA; AMYLOID PRECURSOR PROTEIN BETA; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; LITHIUM; MOOD STABILIZER; NEUROFILAMENT PROTEIN; NEUROLEPTIC AGENT; TAU PROTEIN; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; BIOLOGICAL MARKER;

ADULT; AGE; ALZHEIMER DISEASE; ARTICLE; BIPOLAR DISORDER; CEREBROSPINAL FLUID ANALYSIS; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG USE; FEMALE; HEALTH STATUS; HUMAN; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NERVE DEGENERATION; NEUROPSYCHOLOGICAL TEST; STRUCTURED CLINICAL INTERVIEW FOR DSM DISORDERS; TASK PERFORMANCE; VARIANCE; YOUNG MANIA RATING SCALE; CASE CONTROL STUDY; CEREBROSPINAL FLUID; METABOLISM; MIDDLE AGED; PSYCHOLOGY;

ADULT; AMYLOID BETA-PEPTIDES; BIOMARKERS; BIPOLAR DISORDER; CASE-CONTROL STUDIES; COGNITION DISORDERS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; TAU PROTEINS;

EID: 84957595866     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0127100     Document Type: Article

References (42)

1. Phillips ML, Kupfer DJ. Bipolar disorder diagnosis: challenges and future directions. Lancet. 2013;381(9878):1663-71. doi: 10.1016/S0140-6736 (13) 60989-7 PMID: 23663952.
2. Merikangas KR, Jin R, He JP, Kessler RC, Lee S, Sampson NA, et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Archives of general psychiatry. 2011;68(3):241-51. doi: 10.1001/archgenpsychiatry.2011.12 PMID: 21383262; PubMed Central PMCID: PMC3486639.
3. Ekman M, Granstrom O, OmerovS, Jacob J, Landen M. The societal cost of bipolar disorder in Sweden. Social psychiatry and psychiatric epidemiology. 2013. doi: 10.1007/s00127-013-0724-9 PMID: 23754681.
4. Andreou C, Roesch-Ely D, Veckenstedt R, Bohn F, Aghotor J, Kother U, et al. Predictors of early stable symptomatic remission after an exacerbation of schizophrenia: The significance of symptoms, neuropsychological performance and cognitive biases. Psychiatry research. 2013. doi: 10.1016/j.psychres.2013.08.019 PMID: 23998362.
5. Arts B, Jabben N, Krabbendam L, van Os J. Meta-analyses of cognitive functioning in euthymic bipolar patients and their first-degree relatives. Psychological medicine. 2008;38(6):771-85. doi: 10.1017/S0033291707001675 PMID: 17922938.
6. Torres IJ, Boudreau VG, Yatham LN. Neuropsychological functioning in euthymic bipolar disorder: a meta-analysis. Acta psychiatrica Scandinavica Supplementum. 2007; (434:): 17-26. doi: 10.1111/j. 1600-0447.2007.01055.x PMID: 17688459.
7. Bourne C, Aydemir O, Balanza-Martinez V, Bora E, Brissos S, Cavanagh JT, et al. Neuropsychological testing of cognitive impairment in euthymic bipolar disorder: an individual patient data meta-analysis. Acta psychiatrica Scandinavica. 2013;128(3):149-62. doi: 10.1111/acps.12133 PMID: 23617548.
8. Bora E, Yucel M, Pantelis C. Cognitive endophenotypes of bipolar disorder: a meta-analysis of neuropsychological deficits in euthymic patients and their first-degree relatives. Journal of affective disorders. 2009;113(1-2):1-20. doi: 10.1016/j.jad.2008.06.009 PMID: 18684514.
9. Torrent C, Martinez-Aran A, del Mar Bonnin C, Reinares M, Daban C, Sole B, et al. Long-term outcome of cognitive impairment in bipolar disorder. The Journal of clinical psychiatry. 2012;73(7):e899-905. doi: 10.4088/JCP.11m07471 PMID: 22901360.
10. Mora E, Portella MJ, Forcada I, Vieta E, MurM. Persistence of cognitive impairment and its negative impact on psychosocial functioning in lithium-treated, euthymic bipolar patients: a 6-year follow-up study. Psychological medicine. 2013;43(6):1187-96. doi: 10.1017/S0033291712001948 PMID: 22935452.
11. Kempton MJ, Geddes JR, Ettinger U, Williams SC, Grasby PM. Meta-analysis, database, and meta-regression of 98 structural imaging studies in bipolar disorder. Archives of general psychiatry. 2008;65(9):1017-32. doi: 10.1001/archpsyc.65.9.1017 PMID: 18762588.
12. Lim CS, Baldessarini RJ, Vieta E, Yucel M, Bora E, Sim K. Longitudinal neuroimaging and neuropsychological changes in bipolar disorder patients: review of the evidence. Neuroscience and biobehavioral reviews. 2013;37(3):418-35. doi: 10.1016/j.neubiorev. 2013.01.003 PMID: 23318228.
13. Savitz J, Solms M, Ramesar R. Neuropsychological dysfunction in bipolar affective disorder: a critical opinion. Bipolar disorders. 2005;7(3):216-35. doi: 10.1111/j.1399-5618.2005.00203.x PMID: 15898960.
14. Weinberger DR, McClure RK. Neurotoxicity, neuroplasticity, and magnetic resonance imaging morphometry: what is happening in the schizophrenic brain? Archives of general psychiatry. 2002;59(6):553-8. PMID: 12044198.
15. Jakobsson J, Bjerke M, Ekman CJ, Sellgren C, Johansson AG, Zetterberg H, et al. Elevated Concentrations of Neurofilament Light Chain in the Cerebrospinal Fluid of Bipolar Disorder Patients. Neuropsychopharmacology. 2014. doi: 10.1038/npp. 2014.81 PMID: 24694925.
16. Jakobsson J, Zetterberg H, Blennow K, Johan Ekman C, Johansson A, Landén M. Altered concentrations of amyloid precursor protein metabolites in the cerebrospinal fluid of patients with bipolar disorder. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology. 2013;38(4):664-72. doi: 10.1038/npp. 2012.231 PMID: 23212456
17. Turner PR, O'Connor K, Tate WP, Abraham WC. Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory. Progress in neurobiology. 2003;70(1):1-32. PMID: 12927332.
18. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nature reviews Neurology. 2010;6(3):131-44. doi: 10.1038/nrneurol.2010.4 PMID: 20157306.
19. Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Annals of neurology. 2006;59(3):512-9. doi: 10.1002/ana.20730 PMID: 16372280.
20. Rosengren LE, Karlsson JE, Karlsson JO, Persson LI, Wikkelso C. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem. 1996;67(5):2013-8. PMID: 8863508.
21. Rolstad S, Berg AI, Bjerke M, Johansson B, Zetterberg H, Wallin A. Cerebrospinal fluid biomarkers mirror rate of cognitive decline. Journal of Alzheimer's disease: JAD. 2013;34(4):949-56. doi: 10.3233/JAD-121960 PMID: 23313924.
22. Ryden E, Thase ME, Straht D, Aberg-Wistedt A, BejerotS, Landen M. A history of childhood attentiondeficit hyperactivity disorder (ADHD) impacts clinical outcome in adult bipolar patients regardless of current ADHD. Acta psychiatrica Scandinavica. 2009;120(3):239-46. doi: 10.1111/j.1600-0447.2009. 01399.x PMID: 19426162.
23. Sachs GS, Thase ME, Otto MW, Bauer M, Miklowitz D, Wisniewski SR, et al. Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biological psychiatry. 2003;53(11):1028-42. PMID: 12788248.
24. Association AP. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition: DSM-IV-TR: American Psychiatric Association; 2000.
25. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M. I. N. I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. The Journal of clinical psychiatry. 1998;59 Suppl 20:22-33; quiz 4-57. PMID: 9881538.
26. Saunders JB, Aasland OG, BaborTF, de laFuente JR, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption-II. Addiction. 1993;88(6):791-804. PMID: 8329970.
27. Zetterberg H, Andreasson U, Hansson O, Wu G, Sankaranarayanan S, Andersson ME, et al. Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. Archives of neurology. 2008;65(8):1102-7. doi: 10.1001/archneur.65.8.1102 PMID: 18695061.
28. Olsson A, Vanderstichele H, Andreasen N, De MeyerG, Wallin A, Holmberg B, et al. Simultaneous measurement of beta-amyloid (1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clinical chemistry. 2005;51(2):336-45. doi: 10.1373/clinchem.2004.039347 PMID: 15563479.
29. Yatham LN, Torres IJ, Malhi GS, Frangou S, Glahn DC, Bearden CE, et al. The International Society for Bipolar Disorders-Battery for Assessment of Neurocognition (ISBD-BANC). Bipolar disorders. 2010;12(4):351-63. doi: 10.1111/j.1399-5618.2010.00830.x PMID: 20636632.
30. Lezak M, Howieson D, Bigler E, Tranel D. Neuropsychological Assessment: USA: Oxford University Press; 2012.
31. Strauss E, Sherman EMS, Spreen O. A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary: Oxford University Press; 2006. PMID: 17067774
32. Bearden CE, Shih VH, Green MF, Gitlin M, Sokolski KN, Levander E, et al. The impact of neurocognitive impairment on occupational recovery of clinically stable patients with bipolar disorder: a prospective study. Bipolar disorders. 2011;13(4):323-33. doi: 10.1111/j.1399-5618.2011.00928.x PMID: 21843272; PubMed Central PMCID: PMC3157039.
33. Palsson E, Figueras C, Johansson AG, Ekman CJ, Hultman B, Ostlind J, et al. Neurocognitive function in bipolar disorder: a comparison between bipolar I and II disorder and matched controls. BMC psychiatry. 2013;13:165. doi: 10.1186/1471-244X-13-165 PMID: 23758923; PubMed Central PMCID: PMC3691847.
34. Smith EE, Jonides J. Storage and executive processes in the frontal lobes. Science. 1999;283(5408):1657-61. PMID: 10073923.
35. Schwarz L, Penna S, NovackT. Factors contributing to performance on the Rey Complex Figure Test in individuals with traumatic brain injury. The Clinical neuropsychologist. 2009;23(2):255-67. doi: 10. 1080/13854040802220034 PMID: 19172529.
36. Page RM, Baumann K, Tomioka M, Perez-Revuelta BI, Fukumori A, Jacobsen H, et al. Generation of Abeta38 and Abeta42 is independently and differentially affected by familial Alzheimer disease-associated presenilin mutations and gamma-secretase modulation. The Journal of biological chemistry. 2008;283(2):677-83. doi: 10.1074/jbc. M708754200 PMID: 17962197.
37. Schoonenboom NS, Mulder C, Van Kamp GJ, Mehta SP, Scheltens P, Blankenstein MA, et al. Amyloid beta 38, 40, and 42 species in cerebrospinal fluid: more of the same? Annals of neurology. 2005;58(1):139-42. doi: 10.1002/ana.20508 PMID: 15984010.
38. Kuperstein I, Broersen K, Benilova I, Rozenski J, Jonckheere W, Debulpaep M, et al. Neurotoxicity of Alzheimer's disease Abeta peptides is induced by small changes in the Abeta42 to Abeta40 ratio. The EMBO journal. 2010;29(19):3408-20. doi: 10.1038/emboj.2010.211 PMID: 20818335; PubMed Central PMCID: PMC2957213.
39. Bittner T, Fuhrmann M, Burgold S, Jung CK, Volbracht C, Steiner H, et al. Gamma-secretase inhibition reduces spine density in vivo via an amyloid precursor protein-dependent pathway. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2009;29(33):10405-9. doi: 10.1523/JNEUROSCI.2288-09.2009 PMID: 19692615.
40. Kessing LV, Andersen PK. Does the risk of developing dementia increase with the number of episodes in patients with depressive disorder and in patients with bipolar disorder? Journal of neurology, neurosurgery, and psychiatry. 2004;75(12):1662-6. doi: 10.1136/jnnp. 2003.031773 PMID: 15548477; PubMed Central PMCID: PMC1738846.
41. Damadzic R, Shuangshoti S, Giblen G, Herman MM. Neuritic pathology is lacking in the entorhinal cortex, subiculum and hippocampus in middle-aged adults with schizophrenia, bipolar disorder or unipolar depression. Acta neuropathologica. 2002;103(5):488-94. doi: 10.1007/s00401-001-0496-2 PMID: 11935265.
42. Zetterberg H, Pedersen M, Lind K, Svensson M, Rolstad S, Eckerstrom C, et al. Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years. Journal of Alzheimer's disease: JAD. 2007;12(3):255-60. PMID: 18057559.